Navigation Links
Intarcia Therapeutics Announces Upcoming Presentation at 34th Annual J.P. Morgan Healthcare Conference
Date:1/7/2016

BOSTON, Jan. 7, 2016 /PRNewswire/ -- Intarcia Therapeutics, Inc. today announced that Chairman, President and CEO Kurt Graves will present a Company overview at 9:00 am Pacific Time on Monday, January 11th, at the J.P. Morgan 34th Annual Healthcare Conference. The presentation will be given in the Elizabethan Meeting Room (C & D) at the Westin St. Francis Hotel, San Francisco, CA.

About Intarcia Therapeutics

Intarcia Therapeutics, Inc. is a biopharmaceutical company developing novel therapies to enhance treatment outcomes by optimizing and improving the efficacy, continuous administration for better adherence rates over time, and improved tolerability of drug therapies. Delivering medicines just once or twice yearly in Intarcia's proprietary technologies has the potential to improve efficacy as well as patient adherence and compliance, which is very poor in most chronic diseases. Intarcia's drug development expertise and competitive edge are demonstrated by its abilities to stabilize proteins, peptides and antibody fragments at above-body temperatures for long periods of time and to deliver them in a precise and consistent manner over the course of a full year. Intarcia has nearly completed conducting its Phase 3-stage development program for type 2 diabetes. It consisted of four separate clinical trials. The results of those trials are now being prepared for filings. Intarcia continues to conduct research and development, utilizing its platform technology, to treat other chronic serious disorders in the field of diabetes, obesity and autoimmune disorders. For more information on the Company, please visit http://www.intarcia.com.

Logo - http://photos.prnewswire.com/prnh/20050301/SFTU126LOGO

 


'/>"/>
SOURCE Intarcia Therapeutics, Inc.
Copyright©2016 PR Newswire.
All rights reserved


Related medicine technology :

1. Intarcia Announces New Top-Line Phase 3 Results For Investigational Therapy ITCA 650 In Type 2 Diabetes
2. Intarcia Announces Presentations At ADA Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 -- A GLP-1 RA For Type 2 Diabetes
3. Intarcia To Announce Key ITCA 650 Phase 3 Findings And Other Data Presentations At Upcoming 75th Scientific Sessions of the American Diabetes Association In Boston
4. Intarcia Exercises Re-Opener For Its Recently Closed Royalty / Equity Convert Financing - Raising Total To $300 Million
5. Intarcia Named To "CNBC Disruptor 50" List: One Of Only Two Biopharma Companies Named
6. Intarcia Names Top Commercial Expert Michael Williams As COO; Will Chair Commercial Committee And Lead ITCA 650 Launch In U.S.
7. Intarcia Appoints James P. Brady Vice President, Human Resources
8. Intarcia Therapeutics Closes Novel $225 Million Synthetic Royalty Financing With Equity Conversion Option At $5.5 Billion Valuation
9. Intarcia And Numab Sign Multi-Asset Collaboration To Develop Once-Yearly Therapies In Diabetes, Obesity, and Autoimmune Indications
10. Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results
11. Intarcia Announces Presentation of Phase 3 Data at EASD Showing ITCA 650 Markedly Reduces Blood Sugar In Patients With Poorly Controlled Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/15/2019)... ... 15, 2019 , ... Mold doesn’t need things to be wet in order ... detectable to the eye or by touch. ServPro in Cayucos , the mold ... explaining the conditions that mold needs to grow and how to prevent those conditions. ...
(Date:11/14/2019)... ... 2019 , ... Researchers at Worcester Polytechnic Institute (WPI) are ... blood oxygen levels, a vital indication of the lungs’ effectiveness and whether the ... this miniaturized wearable device will be flexible and stretchable, wireless, inexpensive, and mobile—possibly ...
(Date:11/14/2019)... (PRWEB) , ... November 14, 2019 , ... ... K-FISH, aimed to promote the quality of Korean seafood and enhance its global ... entitled, "K-Seafood Global Weeks" in many countries. These special events are currently ...
Breaking Medicine Technology:
(Date:11/11/2019)... ... November 11, 2019 , ... Early praise for A ... down the complexities of scholarly writing and provides key insight and vital guidance for ... DNP Project will have a permanent place on my bookshelf and will be shared ...
(Date:11/11/2019)... Calif. (PRWEB) , ... November 11, 2019 , ... ... of business support services to dental groups in the United States, today announced ... the community of Lodi, CA. , Patients will enjoy convenient hours, comfortable offices ...
(Date:11/11/2019)... LAS VEGAS (PRWEB) , ... November 11, 2019 , ... ... buyers from 46 different countries including big box buyers like Costco, Walmart, and GNC. ... CBDfx, and GRN to name a few. , This year, CBD.io ...
(Date:11/11/2019)... ... November 11, 2019 , ... Artemis, ... prevention and urges increased adoption of compliance technology in the wake of the ... sold to select retailers in the United States and Canada due to potential ...
(Date:11/11/2019)... ... 11, 2019 , ... PracticeLink Live! Atlanta Physician Career Fair will take place ... 5:00 p.m. and continue until 8:00 p.m. A free, optional seminar for job-seeking physicians, ... 6:30 p.m. , Both the career fair and seminar are open to residents and ...
Breaking Medicine News(10 mins):